Tandem Diabetes Care Inc. (TNDM) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Tandem Diabetes Care’s revenue went from $84M in fiscal 2016 to $1.0B in fiscal 2025, growth of about 31.9% a year.
Net income in fiscal 2025 was -$205M, a net margin of -20.2%; the best year in this period was 2021 with $16M.
Over the twelve months to September 30, 2026, revenue was $1.1B and net income -$49M.
Free cash flow was -$30M in fiscal 2025 and positive in 4 of the 10 years shown.
The diluted share count rose 2101% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.0B | $940M | $748M | $801M | $703M | $499M | $362M | $184M | $108M | $84M |
| Gross profit | $609M | $546M | $490M | $368M | $413M | $376M | $261M | $194M | $90M | $44M | $24M |
| Operating income | -$25M | -$187M | -$99M | -$233M | -$93M | $23M | -$8M | -$17M | -$45M | -$63M | -$78M |
| Net income | -$49M | -$205M | -$96M | -$223M | -$95M | $16M | -$34M | -$25M | -$123M | -$73M | -$83M |
| EPS (diluted) | $-0.70 | $-3.04 | $-1.47 | $-3.43 | $-1.47 | $0.24 | $-0.56 | $-0.42 | $0.02 | $-12.87 | $-27.30 |
| R&D | $188M | $193M | $199M | $170M | $139M | $92M | $64M | $45M | $29M | $21M | $19M |
| Revenue growth | — | +7.9% | +25.7% | −6.7% | +14.0% | +40.9% | +37.7% | +97.0% | +70.9% | +27.7% | +15.7% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15M | -$10M | $24M | -$32M | $50M | $111M | $25M | $42M | -$8M | -$66M | -$61M |
| Capital spending | -$22M | -$20M | -$19M | -$27M | -$34M | -$14M | -$27M | -$20M | -$3M | -$6M | -$9M |
| Free cash flow | -$36M | -$30M | $5M | -$59M | $16M | $97M | -$3M | $22M | -$11M | -$72M | -$70M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | $0 | $30M | $0 | $0 | — | — | — | — | — | — |
| Stock-based pay | $67M | $92M | $101M | $88M | $85M | $61M | $58M | $58M | $24M | $13M | $12M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $293M | $438M | $468M | $617M | $624M | $485M | $176M | $129M | $14M | $54M |
| Debt | — | $444M | $474M | $416M | $420M | $315M | $228M | $20M | — | $83M | $81M |
| Equity | — | $155M | $263M | $314M | $440M | $433M | $366M | $195M | $131M | -$29M | -$6M |
| Total assets | — | $881M | $968M | $953M | $1.1B | $905M | $716M | $326M | $206M | $95M | $112M |
| Shares (diluted) | 70M | 67M | 65M | 65M | 64M | 64M | 61M | 59M | 48M | 6M | 3M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 56.6% | 53.8% | 52.1% | 49.2% | 51.5% | 53.5% | 52.2% | 53.6% | 48.9% | 41.0% | 28.0% |
| Operating margin | -2.4% | -18.4% | -10.5% | -31.2% | -11.6% | 3.2% | -1.6% | -4.6% | -24.3% | -58.5% | -92.6% |
| Net margin | -4.6% | -20.2% | -10.2% | -29.8% | -11.8% | 2.2% | -6.9% | -6.8% | -66.7% | -67.9% | -99.1% |
| FCF margin | -3.4% | -2.9% | 0.5% | -7.8% | 2.0% | 13.8% | -0.5% | 6.2% | -6.2% | -66.8% | -83.2% |
| ROIC | — | -24.7% | -10.6% | -25.3% | -8.5% | 3.0% | -1.3% | -6.1% | -26.9% | -92.8% | -103.8% |
| ROE | — | -131.9% | -36.5% | -71.0% | -21.5% | 3.6% | -9.4% | -12.7% | -93.4% | 250.6% | 1407.9% |
Frequently asked questions
What is Tandem Diabetes Care’s annual revenue?
$1.0B in fiscal 2025 and $1.1B over the twelve months to September 30, 2026.
How much profit does Tandem Diabetes Care make?
Net income was -$205M in fiscal 2025 (net margin -20.2%).
Is Tandem Diabetes Care’s revenue growing?
Yes: revenue rose 7.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.